Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial

Introduction: The randomised, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology [ACR]50) and clearance of skin lesions (Psoria...

Full description

Bibliographic Details
Main Authors: Kristian Reich, Lars Erik Kristensen, Saxon D. Smith, Phoebe Rich, Christophe Sapin, Soyi Liu Leage, Robert McKenzie, Christopher Schuster, Elisabeth Riedl, Melinda Gooderham
Format: Article
Language:English
Published: Mattioli1885 2022-05-01
Series:Dermatology Practical & Conceptual
Subjects:
ixekizumab
adalimumab
SPIRIT-H2H
nail psoriasis
psoriasis
Online Access:https://dpcj.org/index.php/dpc/article/view/1936

Internet

https://dpcj.org/index.php/dpc/article/view/1936

Similar Items